Related references
Note: Only part of the references are listed.The Role of Anti-Inflammatory Drugs in Colorectal Cancer
Dingzhi Wang et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Antibodies to watch in 2013 Mid-year update
Janice M. Reichert
MABS (2013)
TEM8/ANTXR1 Blockade Inhibits Pathological Angiogenesis and Potentiates Tumoricidal Responses against Multiple Cancer Types
Amit Chaudhary et al.
CANCER CELL (2012)
Pharmacokinetic evaluation of axitinib
Brian Patson et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
Why do targeted agents not work in the adjuvant setting in colon cancer?
Basak Oyan
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
Chi-Ping Day et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Antiangiogenic therapy-evolving view based on clinical trial results
Gordon C. Jayson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Xiaoyun Liao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
John M. L. Ebos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Mouse models of advanced spontaneous metastasis for experimental therapeutics
Giulio Francia et al.
NATURE REVIEWS CANCER (2011)
Emotion Recollected in Tranquility: Lessons Learned from the COX-2 Saga
Tilo Grosser et al.
ANNUAL REVIEW OF MEDICINE (2010)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
John F. de Groot et al.
NEURO-ONCOLOGY (2010)
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
Anil Bagri et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Cyclooxygenase-2 in Cancer and Angiogenesis
Mehmet Sahin et al.
ANGIOLOGY (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial
Monica M. Bertagnolli et al.
CANCER PREVENTION RESEARCH (2009)
CANCER The nuances of therapy
Lee M. Ellis et al.
NATURE (2009)
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung
R. E. Harris
INFLAMMOPHARMACOLOGY (2009)
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
Duyen T. Dang et al.
CANCER RESEARCH (2008)
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials - The cross trial safety analysis
Scott D. Solomon et al.
CIRCULATION (2008)
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib
Timothy P. Padera et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells
Pratima Sinha et al.
CANCER RESEARCH (2007)
Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells
GF Wu et al.
CARDIOVASCULAR RESEARCH (2006)
Hypoxia-inducible factor-1α promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts
DT Dang et al.
CANCER RESEARCH (2006)
Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas
R Wu et al.
CLINICAL CANCER RESEARCH (2005)
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
DJ Graham et al.
LANCET (2005)
Expansion of myeloid immune suppressor Gr+CD11b+cells in tumor-bearing host directly promotes tumor angiogenesis
L Yang et al.
CANCER CELL (2004)
Share Paper
